Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000400936

Medchemexpress LLC Miransertib hydrochloride | 1313883-00-9 | 99.7% | 468.98 | 5 MG
SDP

Catalog No. 5000400936
Encompass_Preferred

Miransertib hydrochloride is a potent, orally active, selective, and allosteric Akt inhibitor, effective against Akt1, Akt2, and Akt3 with IC50s of 2.7 nM, 14 nM, and 8.1 nM respectively. It also inhibits the AKT1-E17K mutant protein, making it a potential candidate for research into PI3K/AKT-driven tumors and Proteus syndrome. Additionally, it shows effectiveness against Leishmania.

  • Potent Akt inhibitor (Akt1 IC50: 2.7 nM, Akt2 IC50: 14 nM, Akt3 IC50: 8.1 nM)
  • Inhibits AKT1-E17K mutant protein
  • Potential for PI3K/AKT-driven tumors and Proteus syndrome research
  • Effective against Leishmania
  • Shows potent anti-proliferative activity in cell lines with PIK3CA/PIK3R1 mutations
  • Inhibits p-Akt (S473) and p-Akt (T308)
  • Good oral bioavailability in rats (62%) and monkeys (49%)
  • Inhibits tumor growth in human xenograft mouse models of endometrial adenocarcinoma

Catalog No. 50-004-00936 Supplier Medchemexpress LLC Supplier No. HY19719A5MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Miransertib hydrochloride is a potent, orally active, selective, and allosteric Akt inhibitor, effective against Akt1, Akt2, and Akt3 with IC50s of 2.7 nM, 14 nM, and 8.1 nM respectively. It also inhibits the AKT1-E17K mutant protein, making it a potential candidate for research into PI3K/AKT-driven tumors and Proteus syndrome. Additionally, it shows effectiveness against Leishmania.

  • Potent Akt inhibitor (Akt1 IC50: 2.7 nM, Akt2 IC50: 14 nM, Akt3 IC50: 8.1 nM)
  • Inhibits AKT1-E17K mutant protein
  • Potential for PI3K/AKT-driven tumors and Proteus syndrome research
  • Effective against Leishmania
  • Shows potent anti-proliferative activity in cell lines with PIK3CA/PIK3R1 mutations
  • Inhibits p-Akt (S473) and p-Akt (T308)
  • Good oral bioavailability in rats (62%) and monkeys (49%)
  • Inhibits tumor growth in human xenograft mouse models of endometrial adenocarcinoma

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.